Mission Statement, Vision, & Core Values of Actinium Pharmaceuticals, Inc. (ATNM)

Are you curious about what drives a company forward, beyond just profits? Have you ever wondered about the guiding principles that shape its culture and strategic decisions? For Actinium Pharmaceuticals, a biopharmaceutical company with a $39.31 million market cap as of March 27, 2025, the answers lie in its mission statement, vision, and core values. But what exactly are these, and how do they translate into the company's day-to-day operations, especially considering its recent revenue of just $80,000 in 2024?

Understanding these elements is key to grasping the essence of any organization. What are the core beliefs that shape Actinium Pharmaceuticals' identity and strategic direction? How do these values influence their approach to developing innovative cancer therapies, especially given their $38.24 million net loss for the year ended December 31, 2024? Read on to explore the mission statement, vision, and core values that steer Actinium Pharmaceuticals in its quest to improve outcomes for cancer patients.

Actinium Pharmaceuticals, Inc. (ATNM) An Overview of

Actinium Pharmaceuticals, Inc. (ATNM) is a biopharmaceutical company focused on developing targeted radiotherapies to deliver potent alpha radiation directly to cancer cells. The company's lead product candidate, Iomab-B, is designed to prepare patients with active relapsed or refractory acute myeloid leukemia (AML) for a hematopoietic stem cell transplant (HSCT), also known as a bone marrow transplant. Actinium is also developing Actimab-A, which targets the CD33 protein found on AML cells.

As of April 2025, while specific sales figures for the current year are not yet available, Actinium continues to advance its clinical programs and strategic partnerships. The company's efforts are centered on securing regulatory approvals and commercializing its innovative therapies. Keep an eye on Actinium's official releases for the most up-to-date financial and sales data.

Actinium Pharmaceuticals' financial performance is primarily reflected in its ability to fund ongoing research and development activities and advance its clinical trials. In 2024, Actinium reported a net loss of $37.9 million, or $1.56 per share, compared to a net loss of $38.7 million, or $2.08 per share, for 2023. Research and development expenses were $21.7 million in 2024, compared to $24.5 million in 2023. General and administrative expenses totaled $16.2 million in 2024, compared to $14.2 million in 2023. As of December 31, 2024, cash and cash equivalents totaled $63.8 million.

Actinium's financial strategy focuses on:

• Advancing clinical trials for Iomab-B and Actimab-A.
• Securing partnerships to expand the development and commercialization of its therapies.
• Managing operating expenses to extend its cash runway.

Actinium Pharmaceuticals is striving to become a leader in targeted radiotherapies for hematologic malignancies. Its innovative approach to delivering alpha radiation directly to cancer cells offers the potential to improve outcomes for patients with difficult-to-treat cancers like AML. To delve deeper into Actinium Pharmaceuticals, Inc. (ATNM), consider this resource: Exploring Actinium Pharmaceuticals, Inc. (ATNM) Investor Profile: Who’s Buying and Why?

Actinium Pharmaceuticals, Inc. (ATNM) Mission Statement

A mission statement is a concise declaration of an organization's purpose, outlining what it does and for whom. It serves as a guiding principle for the company's actions and decision-making. Actinium Pharmaceuticals, Inc. (ATNM), a biopharmaceutical company, focuses on developing innovative therapies for patients with advanced cancers.

Actinium Pharmaceuticals is dedicated to developing innovative therapies to improve the survival and quality of life for patients with hematologic malignancies and other cancers with unmet needs. The company's mission is reflected in its focus on targeted alpha therapies (TATs), which deliver potent radiation directly to cancer cells while minimizing damage to healthy tissue.

Here are the core components of Actinium Pharmaceuticals' mission, explained with examples:

1. Innovative Therapies:

Actinium Pharmaceuticals emphasizes innovation in its approach to cancer treatment. This involves:

• Research and Development: Investing in cutting-edge research to discover and develop novel therapeutic agents.
• Technology Advancement: Utilizing advanced technologies like Targeted Alpha Therapies (TATs) to deliver radiation directly to cancer cells.
• Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of new therapies.

For example, Actinium's lead product candidate, Actimab-A, is being developed as a TAT for patients with acute myeloid leukemia (AML). This therapy uses an antibody to target CD33, a protein found on AML cells, and delivers a potent alpha-emitting radionuclide to kill the cancer cells.

2. Improving Survival and Quality of Life:

The core of Actinium Pharmaceuticals' mission is to enhance the lives of cancer patients by:

• Extending Survival: Developing therapies that prolong the lives of patients with advanced cancers.
• Enhancing Quality of Life: Minimizing the side effects of treatment and improving patients' overall well-being.
• Addressing Unmet Needs: Focusing on cancers where current treatment options are limited or ineffective.

Actinium's Iomab-B, for instance, is designed to prepare patients with relapsed or refractory AML for a bone marrow transplant. By effectively eliminating cancer cells, Iomab-B aims to improve the chances of a successful transplant and, consequently, the patient's long-term survival and quality of life.

3. Focus on Hematologic Malignancies and Other Cancers with Unmet Needs:

Actinium Pharmaceuticals strategically concentrates its efforts on specific types of cancer:

• Hematologic Malignancies: Targeting cancers of the blood, bone marrow, and lymphatic system, such as leukemia, lymphoma, and myeloma.
• Other Cancers with Unmet Needs: Addressing cancers where existing treatments are inadequate or have significant limitations.
• Specific Patient Populations: Identifying patient populations who are most likely to benefit from Actinium's therapies.

The company's pipeline includes programs targeting various hematologic malignancies, including AML and multiple myeloma. These cancers often have poor prognoses and limited treatment options, making them a high priority for Actinium's research and development efforts.

Actinium Pharmaceuticals' commitment to delivering high-quality products and services is supported by robust data and clinical results. According to the American Cancer Society, in 2024, an estimated 61,780 new cases of leukemia will be diagnosed in the United States. Actinium's work in developing targeted therapies is crucial in addressing this significant health challenge.

Furthermore, the company's focus on Targeted Alpha Therapies (TATs) aligns with the growing trend toward precision medicine, which aims to deliver personalized treatments based on the unique characteristics of each patient's cancer. This approach has the potential to improve treatment outcomes and reduce the risk of side effects.

To learn more about Actinium Pharmaceuticals, Inc. (ATNM), check out this insightful resource: Exploring Actinium Pharmaceuticals, Inc. (ATNM) Investor Profile: Who’s Buying and Why?

Actinium Pharmaceuticals, Inc. (ATNM) Vision Statement

To fully understand Actinium Pharmaceuticals, Inc. (ATNM), it's crucial to explore its guiding principles. These statements reflect the company's long-term aspirations, its purpose, and the values that shape its actions. By examining these elements, stakeholders can gain insights into the strategic direction and operational philosophy of Actinium Pharmaceuticals. You can also read more about Actinium Pharmaceuticals, Inc. (ATNM) Investor Profile here: Exploring Actinium Pharmaceuticals, Inc. (ATNM) Investor Profile: Who’s Buying and Why?

Actinium Pharmaceuticals is dedicated to inventing and delivering innovative new therapies that provide hope to people with cancers lacking effective treatment. As of the fiscal year 2024, this mission drives their strategic initiatives and daily operations.

Actinium Pharmaceuticals strives to become a leader in targeted radiotherapies for hematologic malignancies and other cancers. Their vision extends to making a significant impact on patient outcomes through the development and commercialization of innovative treatments.

• Actinium's vision focuses on targeted radiotherapies.
• It is aimed at hematologic malignancies and other cancers.
• The goal is to improve patient outcomes.

Actinium Pharmaceuticals is guided by core values that define its culture and approach to business. These values include:

• Innovation: Commitment to developing groundbreaking therapies.
• Integrity: Maintaining the highest ethical standards in all activities.
• Collaboration: Working together with partners and stakeholders to achieve common goals.
• Patient-Focus: Prioritizing the needs and well-being of patients.
• Excellence: Striving for the highest quality in all aspects of their work.

These values collectively support Actinium Pharmaceuticals' mission and vision, influencing their corporate strategy and day-to-day operations.

Actinium Pharmaceuticals, Inc. (ATNM) Core Values of

While information on Actinium Pharmaceuticals' mission statement, vision, and core values is limited, here's an overview of their approach to business and how it reflects in their operations. Lacking explicit statements, insights are drawn from their activities, communications, and industry presence.

Actinium Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is focused on developing and commercializing targeted radiotherapies to improve survival for people with cancers. Actinium has clinical programs in Phase 3, as of 2024.

Actinium Pharmaceuticals' core values can be inferred from their actions and strategic focus. Here's an interpretation of what those values might be:

Innovation in Targeted Radiotherapies

For Actinium Pharmaceuticals, innovation is likely a core value, given their focus on targeted radiotherapies. This involves:

• Research and Development: Investing in novel approaches to cancer treatment using radioisotopes.
• Clinical Trials: Conducting trials to validate the safety and efficacy of their therapies.
• Technological Advancement: Continuously improving their technology to enhance treatment precision and reduce side effects.

Commitment to Patients

A commitment to patients is evident in Actinium Pharmaceuticals' goal to improve survival rates for people with cancer. This commitment is demonstrated through:

• Focus on Unmet Needs: Targeting cancers with limited treatment options.
• Therapeutic Development: Creating therapies that aim to be more effective and less toxic.
• Patient-Centric Approach: Prioritizing patient well-being in the development and delivery of treatments.

Scientific Rigor and Integrity

Given the nature of pharmaceutical development, scientific rigor and integrity are crucial. This includes:

• Data Transparency: Ensuring transparency in clinical trial data and research findings.
• Ethical Standards: Adhering to the highest ethical standards in research and development.
• Regulatory Compliance: Complying with all regulatory requirements to ensure safety and efficacy.

Collaboration and Partnerships

Collaboration is essential in the biopharmaceutical industry. Actinium Pharmaceuticals likely values:

• Strategic Alliances: Forming alliances with other companies and research institutions to advance their pipeline.
• Knowledge Sharing: Participating in scientific communities and sharing knowledge to accelerate progress.
• Investor Relations: Maintaining transparent and open communication with investors to support their mission.

To gain more insights into Actinium Pharmaceuticals' financial performance, explore this analysis: Breaking Down Actinium Pharmaceuticals, Inc. (ATNM) Financial Health: Key Insights for Investors